Clinical Trial Update: Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas

View source ↗

Summary

This update describes an intermediate-size expanded access program for ONC201 in patients with H3 K27M-mutant diffuse midline glioma. The trial status is listed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Midline Glioma H3 K27m-mutant

Drugs mentioned

• ONC201 (ONC201)

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: Glioma, H3 K27M | Status: APPROVED_FOR_MARKETING